MedCan Trend Report 2026 – an Overview

The Trend Report 2026 reveals a clear societal paradox: although medical cannabis is now widely accepted among the German population, many patients still hide their therapy due to fear of stigma. Data from more than 7,000 MCOS patients and a representative YouGov survey show strong medical effectiveness — especially for sleep disorders, pain, and the reduction of conventional pharmaceuticals — yet a deeply rooted experience of prejudice persists in everyday life, in GP practices, and at the workplace. This stigma leads to risky concealment, which can negatively affect medical care and drug safety.

Key Survey Findings

Therapeutic success & medical effects

• 70% report significantly improved sleep and mental recovery.
• 49% feel noticeably more productive and pain-free in daily life and at work.
• 71% were able to completely discontinue painkillers, opioids, or sleeping pills.
• 20% reduced their dosage by more than half.
• Only 0.8% experienced no change.

Societal acceptance

• 75.1% of Germans accept medical cannabis like any other prescription medication.
• 65–69% consider its use in family, social, or workplace settings unproblematic.

Stigma & concealment

• 74% of patients still feel stigmatized.
• 64% do not inform their GP practice about their therapy.
• 33% hide it due to fear of judgment.
• 29% experienced rejection from medical staff.
• 71% do not openly discuss their treatment at work.
• 25% report discrimination in their job.

Increase Acceptance, Minizing Stigmata

To increase acceptance of medical cannabis, we need to treat it with the same pharmaceutical rigor patients already expect from conventional therapies. Platforms like ingredientpharm’s formulation system play a decisive role: by transforming cannabinoids into precisely dosed, stable, and clinically familiar dosage forms—granules, pellets, oils, modified‑release formats—medical cannabis becomes recognizably “medicine” rather than a stigmatized plant. This shift toward standardized, reproducible, GMP‑aligned formulations helps clinicians feel confident prescribing, and helps patients feel safe disclosing their therapy.

References

[1] MedCanOneStop (MCOS GmbH), press release, Sept 01, 2026; link